DIAGNOSTIC VALUE OF A SINGLE SERUM THYROGLOBULIN DETERMINATION ON AND OFF THYROID SUPPRESSIVE THERAPY IN THE FOLLOW‐UP OF PATIENTS WITH DIFFERENTIATED THYROID CANCER
- 1 October 1985
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 23 (4) , 405-411
- https://doi.org/10.1111/j.1365-2265.1985.tb01098.x
Abstract
To assess the significance of a single serum thyroglobulin (Tg) determination on and off thyroid suppressive therapy, serum Tg measurements have been performed in 349 serum samples from 82 patients with differentiated thyroid cancer. All samples were collected after total thyroidectomy with or without subsequent ablation of residual thyroid tissue by radioiodine. One hundred and fifty-three samples were obtained while the patients were on thyroid suppressive therapy and 196 after withdrawal of medication. The results of serum Tg assays were analysed in relation to the presence or absence of residual or metastatic thyroid tissue, as assessed by clinical and laboratory evaluation, including 131I whole body scan. In patients with thyroid residue but no metastases, undetectable serum Tg (false negative results) occurred in 45% of cases off therapy and in 92.9% of cases during therapy. In the presence of metastases no undetectable serum Tg result was found in patients off therapy, while four (6.9%) out of 58 samples from patients with bone and/or lung metastases and seven (31.8%) out of 22 samples from patients with lymph node metastases alone were undetectable (falsely negative) during suppressive therapy. Serum Tg was undetectable in sera from patients with no evidence of thyroid residue or metastatic disease in all but one (1.7%) of 59 samples on and three (5.4%) of 56 samples off suppressive therapy. These Tg results were confirmed to be truly rather than falsely positive, since evidence of metastatic disease was obtained by whole body scan after the administration of therapeutic doses of 131I. These data indicate that the finding of detectable serum Tg during suppressive therapy is a reliable indicator of metastatic disease, while a negative result does not exclude the presence of metastases especially in the case of lymph node involvement. In this regard assays performed off therapy have greater diagnostic value.This publication has 22 references indexed in Scilit:
- Thyroglobulin may be undetectable in the serum of patients with metastatic disease secondary to differentiated thyroid carcinoma. Follow-up of differentiated thyroid carcinomaCancer, 1984
- Evaluation of a solid-phase immunoradiometric assay (IRMA) for serum thyroglobulin: effect of anti-thyroglobulin autoantibodyClinica Chimica Acta; International Journal of Clinical Chemistry, 1982
- A Comparison of Serum Thyroglobulin Measurements and Whole Body 131l Scanning in the Management of Treated Differentiated Thyroid CarcinomaAustralian and New Zealand Journal of Medicine, 1982
- Serum thyroglobulin in the management of patients with thyroid cancerArchives of internal medicine (1960), 1982
- SERUM THYROGLOBULIN IN THYROID CANCERThe Lancet, 1981
- SERUM THYROGLOBULIN CONCENTRATIONS AND 131I WHOLE BODY SCANS IN THE DIAGNOSIS OF METASTASES FROM DIFFERENTIATED THYROID CARCINOMA (AFTER THYROIDECTOMY)Clinical Endocrinology, 1980
- Serum thyroglobulin concentrations and whole-body radioiodine scan in follow-up of differentiated thyroid cancer after thyroid ablation.BMJ, 1979
- SERUM THYROGLOBULIN IN THE DIAGNOSIS AND MANAGEMENT OF THYROID CARCINOMAClinical Endocrinology, 1979
- SERUM THYROGLOBULIN AND RECURRENT THYROID CANCERThe Lancet, 1977
- A radioimmunoassay for serum rat thyroglobulin. Physiologic and pharmacological studies.Journal of Clinical Investigation, 1975